JP2010524937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524937A5 JP2010524937A5 JP2010504069A JP2010504069A JP2010524937A5 JP 2010524937 A5 JP2010524937 A5 JP 2010524937A5 JP 2010504069 A JP2010504069 A JP 2010504069A JP 2010504069 A JP2010504069 A JP 2010504069A JP 2010524937 A5 JP2010524937 A5 JP 2010524937A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- composition
- pharmaceutically acceptable
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92501807P | 2007-04-18 | 2007-04-18 | |
| US60/925,018 | 2007-04-18 | ||
| PCT/US2008/004862 WO2008130552A1 (en) | 2007-04-18 | 2008-04-15 | Triazole derivatives which are smo antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010524937A JP2010524937A (ja) | 2010-07-22 |
| JP2010524937A5 true JP2010524937A5 (enExample) | 2011-05-19 |
| JP5498936B2 JP5498936B2 (ja) | 2014-05-21 |
Family
ID=39433852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504069A Active JP5498936B2 (ja) | 2007-04-18 | 2008-04-15 | Ｓｍｏアンタゴニストであるトリアゾール誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7691887B2 (enExample) |
| EP (1) | EP2136803B1 (enExample) |
| JP (1) | JP5498936B2 (enExample) |
| CN (1) | CN101663033B (enExample) |
| AR (1) | AR066063A1 (enExample) |
| AT (1) | ATE555785T1 (enExample) |
| AU (1) | AU2008241527B2 (enExample) |
| CA (1) | CA2683946C (enExample) |
| CL (1) | CL2008001074A1 (enExample) |
| PE (1) | PE20090806A1 (enExample) |
| TW (1) | TW200901987A (enExample) |
| WO (1) | WO2008130552A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| WO2009086451A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
| US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
| JP2011522773A (ja) * | 2007-12-27 | 2011-08-04 | インフィニティ ファーマスーティカルズ、インク． | 治療剤での癌の処置方法 |
| GB0813740D0 (en) * | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
| JP5816087B2 (ja) * | 2008-08-29 | 2015-11-18 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｓｍｏアンタゴニストとしての飽和二環式複素環誘導体 |
| CA2769795C (en) | 2009-08-05 | 2020-01-07 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
| EP2502078A1 (en) * | 2009-11-20 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| CN104324039A (zh) * | 2014-10-20 | 2015-02-04 | 付茜 | 一种治疗人身体表面脂肪瘤的药剂及使用方法 |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3，3-二氟环丁烷甲酸的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| WO2003065983A2 (en) | 2002-02-01 | 2003-08-14 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| ATE476425T1 (de) | 2003-05-29 | 2010-08-15 | Merck Sharp & Dohme | Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1 |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| JP4903133B2 (ja) | 2004-04-30 | 2012-03-28 | ジェネンテック，インコーポレイティド | ヘッジホッグシグナル伝達のキノキサリン阻害剤 |
| JP2008509146A (ja) | 2004-08-06 | 2008-03-27 | メルク エンド カムパニー インコーポレーテッド | １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのスルホニル化合物 |
| ES2578728T3 (es) | 2004-08-27 | 2016-07-29 | Infinity Pharmaceuticals, Inc. | Proceso para la preparación de compuestos análogos de ciclopamina |
| WO2006028958A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| RU2007119637A (ru) | 2004-10-28 | 2008-12-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве модуляторов hedgehog-пути |
| CA2587489C (en) | 2004-11-03 | 2013-12-31 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| CN103724335A (zh) * | 2005-10-20 | 2014-04-16 | 默沙东公司 | 用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物 |
-
2008
- 2008-04-15 PE PE2008000654A patent/PE20090806A1/es not_active Application Discontinuation
- 2008-04-15 TW TW097113665A patent/TW200901987A/zh unknown
- 2008-04-15 US US12/082,933 patent/US7691887B2/en active Active
- 2008-04-15 CA CA2683946A patent/CA2683946C/en active Active
- 2008-04-15 EP EP08742913A patent/EP2136803B1/en active Active
- 2008-04-15 CN CN2008800127274A patent/CN101663033B/zh active Active
- 2008-04-15 AT AT08742913T patent/ATE555785T1/de active
- 2008-04-15 WO PCT/US2008/004862 patent/WO2008130552A1/en not_active Ceased
- 2008-04-15 JP JP2010504069A patent/JP5498936B2/ja active Active
- 2008-04-15 AR ARP080101540A patent/AR066063A1/es unknown
- 2008-04-15 CL CL2008001074A patent/CL2008001074A1/es unknown
- 2008-04-15 AU AU2008241527A patent/AU2008241527B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9205086B2 (en) | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | |
| JP2008516982A5 (enExample) | ||
| JP2011502958A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| US20130156755A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor | |
| JP2017505762A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2013516393A5 (enExample) | ||
| JP2011507849A5 (enExample) | ||
| US20130171105A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor | |
| JP2014533299A5 (enExample) | ||
| JP2015531366A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2010515715A5 (enExample) | ||
| JP2011517457A5 (enExample) | ||
| JP2009534386A5 (enExample) | ||
| JP2013537229A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| RU2008140940A (ru) | Производное триазола или его соль | |
| JP2008526723A5 (enExample) | ||
| JP2010526814A5 (enExample) | ||
| JP2005500311A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2009536196A5 (enExample) | ||
| JP2005517006A5 (enExample) |